Cytokinetics, Incorporated (NasdaqGS: CYTK)
Health Care · Biotechnology · US
$63.06
+0.24% today · +4.3% 1Y
Cytokinetics, Incorporated (NasdaqGS: CYTK) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.75B and employs 673 people.
Over the last twelve months the share price has gained 4.3%, trading between 54.30 and 88.31.
Tweenvest scores Cytokinetics, Incorporated across four factors: quality 23/100, value 53/100, growth 100/100. Its strongest factor is growth.
CYTK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.75B
- Revenue (TTM)
- $67.67M
- P/E
- —
- EPS
- -7.18
- Dividend yield
- —
- Beta (5Y)
- 0.41
- 52-week high
- $88.31
- 52-week low
- $54.30
- Avg volume (3M)
- —
- Shares outstanding
- 139.02M
- Employees
- 673
- Next earnings
- —
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
- ISIN
- US23282W6057
- Founded
- 1997
- Listed since
- Apr 26, 2004
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Krystal Biotech, Inc.NasdaqGS: KRYS | $9.82B | $331.71 | +0.03% |
| Kymera Therapeutics, Inc.NasdaqGM: KYMR | $9.35B | $110.87 | -1.36% |
| Protagonist Therapeutics, Inc.NasdaqGM: PTGX | $9.30B | $144.79 | +0.74% |
| Arrowhead Pharmaceuticals, Inc.NasdaqGS: ARWR | $8.86B | $60.85 | -3.04% |
| Caris Life Sciences, Inc.NasdaqGS: CAI | $8.39B | $29.02 | -2.29% |
| Spyre Therapeutics, Inc.NasdaqGS: SYRE | $8.01B | $85.66 | -0.04% |
| TG Therapeutics, Inc.NasdaqCM: TGTX | $7.85B | $55.67 | +0.54% |
| ABIVAX Société AnonymeENXTPA: ABVX | $7.71B | €79.00 | +2.46% |
Figures last refreshed Oct 11, 2026.